Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track NTHI with free AI briefings, catalyst countdowns, and dilution alerts.

NTHI · NeOnc Technologies Holdings, In

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$6.2M Cash on Hand
3.8mo Cash Runway
Follow NTHI by email Get an email when NTHI reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about NTHI, unsubscribe in one click. Privacy

📣 What NTHI Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Perillyl Alcohol (NEO100) Residual, Progressive or Recurrent Grade II or III Meningioma Phase 2 · NCT05023018 Recruiting
Temozolomide Perillyl Alcohol Conjugate NEO212 Diffuse Astrocytoma, IDH-Mutant Phase 1/2 · NCT06047379 Recruiting

Also used in these trials (approved or third-party drugs, not NTHI's own candidates): Bevacizumab, Carboplatin, Ziv-Aflibercept, Ipilimumab, Nivolumab, Paclitaxel, Pembrolizumab, Regorafenib.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

NTHI holds $6.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $4.9M/quarter from operations, an estimated runway of 3.8 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 79 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NTHI files for a raise →

👥 Who Owns NTHI

Insiders 56% Institutions (26 holders) 10.9% Public and other holders 33.1%
HolderTypeShares% of sharesAs of
Amir F Heshmatpour
CEO, President, Director, 10% owner
Insider 7,873,140 27.29% 2026-11-13
Thomas C Chen
CMO, Director, 10% owner
Insider 4,690,602 16.26% 2026-11-09
Cinctive Capital Management LP Institution (13G, 5%+) 2,885,779 10.00% 2026-09-30
Ming-fu (alan) Chiang
Director
Insider 2,190,049 7.59% 2025-11-12
Patrick Walters
COO
Insider 876,373 3.04% 2025-03-26
Keithly Garnett
CFO
Insider 281,410 0.98% 2026-09-15
Yousha Neman-Ebrahim
Chief Clinical Officer · +67,000 options
Insider 134,760 0.47% 2026-04-23
David Jr. Suh,
Chief Accounting Officer · +58,334 options
Insider 111,866 0.39% 2026-03-01
Nasim Shomali
Director
Insider 160 0.00% 2026-07-01

Share count 28,850,588 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full NTHI picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NTHI and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.